UnitedHealth, employer of slain exec Brian Thompson, found to have overcharged some cancer patients for drugs by over 1,000%
The report is the latest indictment of America’s broken healthcare system.
FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
Zacks.com on MSN6h
FTC Report Reveals PBM Practices Impacting Competition and Drug Costs
The FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...
Hosted on MSN5h
FTC Slams UnitedHealth (NYSE:UNH), CVS and Cigna PBMs for Inflating Prices by $7.3B
The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...
Honolulu Star-Advertiser9h
FTC: Pharmacy managers inflated drug prices by $7.3 billion
WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...
pharmaphorum9h
FTC doubles down on PBM criticism in new report
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...
Top three insurers reaped $7.3 billion through their drug middlemen's markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
Lawmaker may file bill to regulate PBMs: “They’re managing the dollar bill”
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
FTC releases new findings in drug price inflation investigation
A new report from the Federal Trade Commission is uncovering what appears to be a major driver of the high cost of ...
STAT7h
Pharmalittle: We’re reading about FTC criticizing PBMs, a NIH policy on access to medicines, and more
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...